| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(13)62121-2 |
| P698 | PubMed publication ID | 24209977 |
| P2093 | author name string | Hongmei Mo | |
| Xiao Ding | |||
| John G McHutchison | |||
| William T Symonds | |||
| Phillip S Pang | |||
| Fernando E Membreno | |||
| Eric Lawitz | |||
| Robert H Hyland | |||
| Fred F Poordad | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Preliminary study of two antiviral agents for hepatitis C genotype 1. | Q34030288 | ||
| A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. | Q34030597 | ||
| Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. | Q34320498 | ||
| Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting | Q34577107 | ||
| Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial | Q34649453 | ||
| Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. | Q37851006 | ||
| Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. | Q38111844 | ||
| Novel therapies for hepatitis C - one pill fits all? | Q38117549 | ||
| A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. | Q39432467 | ||
| Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial | Q42857015 | ||
| Exploratory study of oral combination antiviral therapy for hepatitis C. | Q42987725 | ||
| A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. | Q42989590 | ||
| Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial | Q42990184 | ||
| 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. | Q42992965 | ||
| Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders | Q43041150 | ||
| Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. | Q44847210 | ||
| Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report | Q70313812 | ||
| P433 | issue | 9916 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| ribavirin | Q421862 | ||
| Hepatitis C virus | Q708693 | ||
| patient | Q181600 | ||
| sofosbuvir | Q2502747 | ||
| hepatitis C | Q154869 | ||
| ledipasvir | Q15409409 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 515-523 | |
| P577 | publication date | 2013-11-05 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial | |
| P478 | volume | 383 |
| Q39077941 | "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic? |
| Q28546535 | A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients |
| Q36119732 | A Novel Model of Asymptomatic Plasmodium Parasitemia That Recapitulates Elements of the Human Immune Response to Chronic Infection |
| Q85608080 | A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on |
| Q95463423 | A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Dac |
| Q48553648 | A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects |
| Q40688823 | A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? |
| Q33818464 | A consensus for occupational health management of healthcare workers infected with human immunodeficiency virus, hepatitis B virus, and / or hepatitis C virus |
| Q38894120 | A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study |
| Q38578520 | A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation? |
| Q87640700 | A survey of breakthrough therapy designations |
| Q52306466 | A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. |
| Q42400012 | APASL consensus statements and recommendation on treatment of hepatitis C. |
| Q41496602 | Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care |
| Q95561254 | Advances in interferon-free hepatitis C therapy: 2014 and beyond |
| Q38215652 | Advances in newly developing therapy for chronic hepatitis C virus infection |
| Q38581352 | Alcoholic liver disease: Clinical and translational research |
| Q36329125 | Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development |
| Q24193940 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C |
| Q24194815 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C |
| Q40745083 | Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190. |
| Q27022794 | Antiviral therapies for chronic hepatitis C virus infection with cirrhosis |
| Q38221090 | Antiviral therapy for chronic hepatitis C in 2014. |
| Q42207125 | Antiviral treatment of hepatitis C. |
| Q38341993 | Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. |
| Q64285976 | Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir |
| Q35776195 | Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study |
| Q38594613 | Asunaprevir (BMS-650032) for the treatment of hepatitis C virus |
| Q40304601 | Augmentation of hepatitis C virus-specific immunity and sustained virologic response. |
| Q40719246 | Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus |
| Q37709604 | Barriers to the acceptance of work colleagues infected with Hepatitis B and Hepatitis C in Japan |
| Q41921724 | Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients. |
| Q41670432 | Baseline sensitivity of T cells to alpha-IFN correlates with sustained virological response to IFN-based triple therapy in HCV infection |
| Q38204368 | Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir |
| Q39483891 | Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin |
| Q34775524 | CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults |
| Q40942161 | Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q33440436 | Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. |
| Q55494181 | Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis. |
| Q37280593 | Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. |
| Q28075544 | Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection |
| Q92625996 | Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions |
| Q54243856 | Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options. |
| Q40066639 | Continuum of hepatitis C care in France: A 20-year cohort study |
| Q42175896 | Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent |
| Q33831652 | Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals |
| Q41486392 | Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease |
| Q93039596 | Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection |
| Q40931707 | Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. |
| Q58611270 | Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan |
| Q38295798 | Current and future HCV therapy: do we still need other anti-HCV drugs? |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q42781804 | Current treatment of chronic hepatitis C in China: Dilemma and potential problems |
| Q39092871 | Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs |
| Q38545043 | Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis |
| Q31170657 | Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data |
| Q35044909 | Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection |
| Q38665683 | Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens? |
| Q53513928 | Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C. |
| Q38515906 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace |
| Q26741205 | Diabetes mellitus and metformin in hepatocellular carcinoma |
| Q88868398 | Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community |
| Q36531731 | Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus |
| Q35905985 | Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection |
| Q38826176 | Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights |
| Q40118647 | Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). |
| Q38821075 | Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. |
| Q38885160 | Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold |
| Q33955210 | Distinct features in natural history and outcomes of acute hepatitis C. |
| Q39010715 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? |
| Q38432073 | Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications |
| Q38255693 | Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. |
| Q37027342 | Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients |
| Q39449507 | Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response |
| Q28074783 | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis |
| Q89639377 | Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial |
| Q33805907 | Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting |
| Q41750179 | Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: A retrospective study using the Japanese Interferon Database. |
| Q53837635 | Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. |
| Q38837174 | Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q39025640 | Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System |
| Q33168181 | Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C. |
| Q47191023 | Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. |
| Q33862919 | Ending hepatitis C in the United States: the role of screening. |
| Q35031753 | Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C |
| Q35194411 | Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt |
| Q41200675 | Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy |
| Q35832850 | Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study |
| Q96606528 | Factors influencing hepatitis C cure in the era of direct-acting antivirals |
| Q26822400 | Finally sofosbuvir: an oral anti-HCV drug with wide performance capability |
| Q38353529 | Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. |
| Q38218607 | Future treatments of cirrhosis |
| Q34431175 | Global distribution and prevalence of hepatitis C virus genotypes |
| Q30245058 | Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes |
| Q57168365 | HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies |
| Q38707521 | HCV Prevalence in Asian Americans in California |
| Q35090634 | HCV and HIV co-infection: mechanisms and management. |
| Q35535844 | HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. |
| Q28084654 | Hepatitis C |
| Q56898303 | Hepatitis C (chronic) |
| Q26781743 | Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy |
| Q64110249 | Hepatitis C Clinical Dashboards: Improving Liver Specialty Care Access and Quality |
| Q37746733 | Hepatitis C Virus Nonstructural 5A Protein (HCV-NS5A) Inhibits Hepatocyte Apoptosis through the NF-κb/miR-503/bcl-2 Pathway |
| Q33576161 | Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment |
| Q34439125 | Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review |
| Q40637053 | Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. |
| Q37513094 | Hepatitis C eradication with sofosbuvir leads to significant metabolic changes |
| Q34044333 | Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus |
| Q40109851 | Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment |
| Q54277218 | Hepatitis C virus infection in children and adolescents. |
| Q38887954 | Hepatitis C virus resistance to the new direct-acting antivirals |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q28082000 | Hepatitis C virus: Virology, diagnosis and treatment |
| Q26798465 | Hepatitis C: Treatment of difficult to treat patients |
| Q92671150 | Hepatocellular Carcinoma After Successful Treatment of Hepatitis C Virus with Ledipasvir/Sofosbuvir Presenting as Acute Pulmonary Tumor Embolism |
| Q36651317 | High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study |
| Q41489816 | High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? |
| Q34439917 | IFN-λ4: the paradoxical new member of the interferon lambda family |
| Q40480795 | Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes. |
| Q36088575 | Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. |
| Q40338014 | Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir |
| Q35501259 | Impact of all oral anti-hepatitis C virus therapy: A meta-analysis |
| Q38740523 | In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir |
| Q41595435 | In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir |
| Q38689820 | Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation |
| Q38416448 | Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting |
| Q38530211 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. |
| Q40896732 | L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. |
| Q35558268 | Labour productivity losses caused by premature death associated with hepatitis C in Spain. |
| Q40466129 | Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. |
| Q38236179 | Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. |
| Q52593865 | Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. |
| Q38838138 | Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report with review of literature |
| Q41110938 | Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis |
| Q35019918 | Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection |
| Q40393165 | Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study |
| Q41429836 | Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). |
| Q34454200 | Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection |
| Q42205980 | Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. |
| Q36052231 | Ledipasvir/Sofosbuvir. |
| Q34470061 | Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. |
| Q38992214 | Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. |
| Q36166222 | Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. |
| Q26770033 | Management of immunosuppressant agents following liver transplantation: Less is more |
| Q38206862 | Medical co-morbidities and practice |
| Q34452419 | Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus |
| Q38573508 | Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. |
| Q38972180 | Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies |
| Q44104489 | Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. |
| Q33672648 | Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China |
| Q38664453 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir |
| Q26800050 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review |
| Q59350268 | Nonhuman primate models of human viral infections |
| Q38611842 | Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir |
| Q38318678 | Novel interventions to prevent HIV and HCV among persons who inject drugs |
| Q26830643 | Oncogenes and RNA splicing of human tumor viruses |
| Q38295814 | Optimal therapy in genotype 4 chronic hepatitis C: finally cured? |
| Q38893244 | Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review |
| Q36734896 | Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum |
| Q36590755 | PharmGKB summary: peginterferon-α pathway |
| Q30365599 | Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents |
| Q24186846 | Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysis |
| Q37373261 | Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. |
| Q37684017 | Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. |
| Q40305694 | Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. |
| Q36506480 | Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort |
| Q64928335 | Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. |
| Q35735285 | Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia |
| Q38826624 | Prevention and management of treatment failure to new oral hepatitis C drugs. |
| Q38264060 | Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy |
| Q26798477 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications |
| Q42373783 | Ralf Bartenschlager, Charles Rice, and Michael Sofia are honored with the 2016 Lasker~DeBakey Clinical Medical Research Award |
| Q36014286 | Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection |
| Q38959188 | Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature. |
| Q36290416 | Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs |
| Q36100521 | Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study |
| Q40065692 | Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism |
| Q57841264 | Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting |
| Q40228687 | Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV |
| Q39398874 | Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients |
| Q39326974 | Real-world challenges for hepatitis C virus medications: a critical overview |
| Q93140832 | Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment |
| Q36733568 | Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study |
| Q35667907 | Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study |
| Q40667626 | Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies |
| Q26777408 | Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications |
| Q100750198 | Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study |
| Q38213847 | Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects |
| Q47306709 | Retreatment Options Following HCV Direct Acting Antiviral Failure |
| Q47121490 | Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. |
| Q24658656 | Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women? |
| Q38703524 | Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy |
| Q59359369 | Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals |
| Q40787997 | Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis |
| Q26776408 | Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection |
| Q35779058 | Role of genetic polymorphisms in hepatitis C virus chronic infection |
| Q37216507 | SASLT guidelines: Update in treatment of Hepatitis C virus infection |
| Q37719675 | SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
| Q37399645 | Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment |
| Q35995534 | Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis |
| Q38742966 | Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. |
| Q40950331 | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials |
| Q38818416 | Safety of direct antiviral agents in the management of hepatitis C. |
| Q38903835 | Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. |
| Q35491398 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? |
| Q38570745 | Simeprevir and sofosbuvir for treatment of hepatitis C infection |
| Q38216582 | Simeprevir for the treatment of chronic hepatitis C genotype 1 infection |
| Q40821688 | Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study |
| Q42202756 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study |
| Q33774724 | Sofosbuvir |
| Q38785530 | Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report |
| Q33568568 | Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives |
| Q42207118 | Sofosbuvir for the treatment of hepatitis C virus infection |
| Q38383410 | Sofosbuvir for treatment of chronic hepatitis C. |
| Q38205737 | Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks |
| Q38643594 | Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection |
| Q26770024 | Sofosbuvir treatment and hepatitis C virus infection |
| Q55243551 | Sofosbuvir, a New Nucleotide Analogue, for the Treatment of Chronic Hepatitis C Infection. |
| Q38245128 | Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus |
| Q35037688 | Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis |
| Q50283110 | Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection |
| Q24562950 | Sofosbuvir: a novel oral agent for chronic hepatitis C |
| Q38222679 | Sofosbuvir: a review of its use in patients with chronic hepatitis C. |
| Q38180027 | Sofosbuvir: first global approval |
| Q41672541 | Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? |
| Q90648674 | Structural and Epitope Analysis (T- and B-Cell Epitopes) of Hepatitis C Virus (HCV) Glycoproteins: An in silico Approach |
| Q26824046 | Surgical approach for hepatitis C virus-related hepatocellular carcinoma |
| Q39483711 | Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q36270505 | Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein |
| Q35270937 | Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis |
| Q36279638 | The Asian Grocery Store-Based Cancer Education Program: Creating New Education Modules |
| Q39214522 | The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis. |
| Q45347684 | The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response |
| Q90146224 | The case for a universal hepatitis C vaccine to achieve hepatitis C elimination |
| Q35168083 | The changing burden of hepatitis C virus infection in the United States: model-based predictions. |
| Q39137372 | The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. |
| Q38217350 | The current state and future prospects of chronic hepatitis C virus infection treatment |
| Q40326326 | The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. |
| Q64061966 | The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010-2016 |
| Q41075768 | The dollars and sense of chronic hepatitis C infection management |
| Q59330347 | The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study |
| Q54943151 | The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. |
| Q39075044 | The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies |
| Q43034060 | The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? |
| Q35750560 | The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments |
| Q28070260 | Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis |
| Q38581478 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. |
| Q55218109 | Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. |
| Q54268463 | Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. |
| Q38460386 | Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy |
| Q38174244 | Treatment of hepatitis C virus genotype 3-infection |
| Q36519126 | Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. |
| Q40292229 | Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. |
| Q39108672 | Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin |
| Q41923073 | Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population |
| Q92559474 | Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia |
| Q40448499 | Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. |
| Q50262252 | Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients |
| Q64892074 | Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. |
| Q33423299 | Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus |
| Q26865870 | Vertical transmission of hepatitis C virus: systematic review and meta-analysis |
| Q92203399 | Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update |
| Q42254742 | Viral hepatitis: is it the end of the line for interferon therapy for hepatitis C? |
| Q35592257 | Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study |
| Q35594278 | Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study |
| Q38569681 | What does the pharmacological future of treating chronic hepatitis C look like? |
| Q38182243 | What is the future of ribavirin therapy for hepatitis C? |
| Q34447905 | Which therapeutic option for hepatitis C virus genotype 1? |
| Q42683902 | β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development |
Search more.